Compare Recursion Pharmaceuticals Inc (RXRX) vs Invesco Solar ETF (TAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Invesco Solar ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.23 (market cap $1.86B), while Invesco Solar ETF trades at $47.82. Which is the better fit depends on your goals.
| RXRX | TAN | |
|---|---|---|
Market Cap | $1.86B | — |
Sector | Health | Sector/Thematic |
52-Week High | $6.79 | $73.95 |
52-Week Low | $2.84 | $41.78 |
Enterprise Value | $1.38B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
TAN trades at $49.13, up 2.27% today, but technical indicators signal a bearish trend with moving averages showing sell pressure. The solar ETF faces mixed sentiment; recent news highlights policy tailwinds from U.S. tariffs but also sector risks like market saturation and high volatility. Financial ratios are unavailable, limiting fundamental clarity, while institutional activity includes Bank of America increasing its stake in Q1 2026.
Outlook is cautious: geopolitical shifts and AI-driven energy demand offer growth potential, but headwinds include price deflation, regulatory uncertainty, and underperformance versus broad markets. Risks center on expense ratios, drawdowns, and competition, requiring careful evaluation for volatility-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Invesco Solar ETF
TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →
